A collaboration between Olweus group and Yardena Samuels group at the Weizmann Institute of Science, Israel, was published in Cancer Cell in March. Together, they have studied how dysregulation of translation in cancer cells can serve as a source for antigens to target for cancer, and the findings can potentially lead to the development of new immunotherapies targeting cancer-associated antigens generated through aberrant translation events. The contribution from Olweus group has been to screen for immunogenic peptides that can elicit antitumor immune responses.
The publication was featured in Weekly Digests of ACIR (Accelerating Cancer Immunotherapy Research) on April 2 Translation dysregulation in cancer produces targetable antigens
Original publication
Weller C, Bartok O, McGinnis CS, Palashati H, Chang TG, Malko D, Shmueli MD, Nagao A, Hayoun D, Murayama A, Sakaguchi Y, Poulis P, Khatib A, Erlanger Avigdor B, Gordon S, Cohen Shvefel S, Zemanek MJ, Nielsen MM, Boura-Halfon S, Sagie S, Gumpert N, Yang W, Alexeev D, Kyriakidou P, Yao W, Zerbib M, Greenberg P, Benedek G, Litchfield K, Petrovich-Kopitman E, Nagler A, Oren R, Ben-Dor S, Levin Y, Pilpel Y, Rodnina M, Cox J, Merbl Y, Satpathy AT, Carmi Y, Erhard F, Suzuki T, Buskirk AR, Olweus J, Ruppin E, Schlosser A, Samuels Y. Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell. 2025 Mar 21:S1535-6108(25)00082-0. doi: 10.1016/j.ccell.2025.03.003. Epub ahead of print. PMID: 40154482.